CHMFL-BTK-01

• Description :

  CHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Btk

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/chmfl-btk-01.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NC1=CC=CC(C(C=C2NC3=CC=C(C(N4CCOCC4)=O)C(NC(C=C)=O)=C3)=CN(C)C2=O)=C1C)C5=CC=C(C(C)(C)C)C=C5

• Molecular Formula :

  C38H41N5O5

• Molecular Weight :

  647.76

• Precautions :

  P264-P270-P330-P501

• References & Citations :

  [1]Liang Q, et al. Discovery of N- (3- (5- ((3-acrylamido-4- (morpholine-4-carbonyl) phenyl) amino) -1-methyl-6-oxo-1,6-dihydropyridin-3-yl) -2-methylphenyl) -4- (tert-butyl) benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. Eur J Med Chem. 2017 May 5;131:107-125.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2095280-64-9]